Bimekizumab-bkzx Therapeutic Cheat Sheet
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma …
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that in gel form is FDA approved for AIDs-related localized cutaneous Kaposi’s sarcoma (KS)1. As compared to other topical retinoids, alitretinoin is unique in that it binds to all known intracellular retinoid receptors (RARs and RXRs), allowing it to exert anti-proliferative and apoptotic effects, particularly usefu … 
Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, offers a convenient, safe, and effective field treatment of actinic keratosis. We continue our surgical Therapeut … 
Fluconazole is a synthetic triazole with a broader antifungal spectrum than the imidazole class. Resistance to first-pass metabolism and consistent oral absorption are advantages over agents like ketoconazole in the antifungal armamentarium, particularly in the context of the United States Food and Drug Administration’s reinforced warning against oral ketoconazole for skin and nail infections, d … 
The use of antimicrobial therapy in the field of cutaneous surgery can be a difficult and controversial topic. Overall, there are a lack of randomized controlled clinical trials evaluating the efficacy of antimicrobial prophylaxis within our field. As a result, much of the recommendations for antimicrobial prophylaxis are extrapolated from other fields, such as dentistry, cardiology, and orthopedi … 